Drug Profile
Glufosfamide - Eleison Pharmaceuticals
Alternative Names: Beta-D-Glc-IPM; D 19575; Glufosfamide; β-D-Glc-IPMLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Baxter Oncology; German Cancer Research Center
- Developer Baxter Oncology; Eleison Pharmaceuticals; MediBIC; Threshold Pharmaceuticals
- Class Antineoplastics; Oxazines; Phosphoramide mustards; Small molecules
- Mechanism of Action Alkylating agents; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Pancreatic cancer
- No development reported Solid tumours
- Discontinued Ovarian cancer; Small cell lung cancer; Soft tissue sarcoma
Most Recent Events
- 19 Nov 2019 Eleison Pharmaceuticals receives approval from the China Food and Drug Administration (CFDA) to begin enrollment in China for its international phase III trial in Pancreatic cancer
- 19 Nov 2019 Eleison Pharmaceuticals plans to initiate enrollment in a phase III trial for Pancreatic cancer in China
- 21 Nov 2017 Eleison Pharmaceuticals and China Oncology Focus agree to co-promote and co-develop glufosfamide in China and other countries of south-east Asia for Pancreatic cancer